Drug Trial Radar · NCT00825500
Staccato Loxapine in Migraine (Out Patient)
Last checked: Nov 20, 2026Latest source record: Apr 24, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
366
Actual
Start
Jan 2009
Primary completion
Aug 2009
Study completion Aug 2009
Sponsor
- Lead sponsor
- Alexza Pharmaceuticals, Inc.Not stated
- Sponsor type
- Not stated
- First posted
- Jan 21, 2009
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Assess the safety and efficacy of Staccato Loxapine in patients with moderate to severe migraine headache with or without aura in an outpatient setting.
Conditions
- Migraine Headache
Interventions
Inhaled PlaceboDrug
Inhaled Staccato placebo (0 mg)
Inhaled Loxapine 1.25 mgDrug
Inhaled Staccato Loxapine 1.25 mg, single dose
Inhaled Loxapine 2.5 mgDrug
Inhaled Staccato Loxapine 1.25 mg, single dose
Primary outcomes
What the sponsor says the trial is designed to measure.
- Pain-Relief at 2 Hours Post-treatmentTime frame: 2 hours
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Roger K. Cady
Springfield, Missouri
Elkind Headache Center
Mount Vernon, New York
CNS Research, Inc.
East Providence, Rhode Island
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.